Naldemedine + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postoperative Gastrointestinal Dysfunction
Conditions
Postoperative Gastrointestinal Dysfunction
Trial Timeline
Nov 6, 2020 → Jan 4, 2021
NCT ID
NCT04355169About Naldemedine + Placebo
Naldemedine + Placebo is a phase 2 stage product being developed by Shionogi for Postoperative Gastrointestinal Dysfunction. The current trial status is terminated. This product is registered under clinical trial identifier NCT04355169. Target conditions include Postoperative Gastrointestinal Dysfunction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07038551 | Approved | Recruiting |
| NCT04355169 | Phase 2 | Terminated |
| NCT01993940 | Phase 3 | Completed |
| NCT01965652 | Phase 3 | Completed |
| NCT01965158 | Phase 3 | Completed |
| NCT01122030 | Phase 2 | Completed |
Competing Products
20 competing products in Postoperative Gastrointestinal Dysfunction